NewAmsterdam Pharma (NAMS) Net Margin (2023 - 2025)
Historic Net Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 20691.09%.
- NewAmsterdam Pharma's Net Margin fell 206339100.0% to 20691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 627.28%, marking a year-over-year decrease of 352400.0%. This contributed to the annual value of 530.25% for FY2024, which is 7255100.0% up from last year.
- As of Q3 2025, NewAmsterdam Pharma's Net Margin stood at 20691.09%, which was down 206339100.0% from 90.7% recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Net Margin ranged from a high of 57.18% in Q3 2024 and a low of 20691.09% during Q3 2025
- Its 3-year average for Net Margin is 3954.24%, with a median of 1464.96% in 2023.
- In the last 5 years, NewAmsterdam Pharma's Net Margin soared by 54386900bps in 2024 and then crashed by -206339100bps in 2025.
- Quarter analysis of 3 years shows NewAmsterdam Pharma's Net Margin stood at 6160.4% in 2023, then surged by 88bps to 721.71% in 2024, then plummeted by -2767bps to 20691.09% in 2025.
- Its Net Margin stands at 20691.09% for Q3 2025, versus 90.7% for Q2 2025 and 1327.3% for Q1 2025.